Kneat: Global Generics Pharma Leader Selects Kneat

LIMERICK, Ireland, April 09, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX:KSI) (OTCQX:KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a multinational producer of generic pharmaceuticals ("the Company") has signed a Services Agreement with Kneat to digitalize its drawing management process. Drawing management supports engineering and validation processes by digitalizing and organizing all technical drawings, eliminating paper-based errors, maintaining traceability of revisions, and controlling access.Headquartered in Europe and operating over a dozen manufacturing facilities around the world, the Company is a leading provider of generic and biosimilar pharmaceuticals to patients in over 100 countries. With more than 20,000 employees, the Company will initially use Kneat for management of all its engineering drawings at its largest manufacturing site in Europe. Subsequently, the Company can leverage Kneat to streamline and automate all its validation workflows, ensuring efficiency, accuracy, data integrity and adherence to good manufacturing practice."Today's announcement adds another global leader to our customer community. It also showcases the versatility of the Kneat platform, which can be leveraged to deliver additional adjacent functions."- Eddie Ryan, ...Full story available on Benzinga.com